Tumour necrosis factor inhibitors in ankylosing spondylitis

Internal Medicine Journal

Volumn 38, Issue 10, 2008, Pages 781-789

  Reed, M R ^a   Taylor, A L ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Adalimumab; Ankylosing spondylitis; Etanercept; Infliximab; Treatment; Tumour necrosis factor inhibitor

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; LAMIVUDINE; LENERCEPT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ANALGESIA; ANAPHYLAXIS; ANKYLOSING SPONDYLITIS; CANCER RISK; CHILL; CLINICAL ASSESSMENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DRUG CHOICE; DRUG COST; DRUG DOSE COMPARISON; DRUG INDUCED DISEASE; ENTERITIS; FEVER; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEPATITIS B; HUMAN; HYPOTENSION; IMMUNOGENICITY; INFECTION RISK; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE URTICARIA; IRIDOCYCLITIS; KINESIOTHERAPY; LONG TERM CARE; MELANOMA; MILIARY TUBERCULOSIS; MULTIPLE SCLEROSIS; OSTEOPOROSIS; PHYSIOTHERAPY; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN CANCER; SPINAL PAIN; SPINE MOBILITY; SPINE RADIOGRAPHY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS REACTIVATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; IMMUNOGLOBULIN G; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 55349127535     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2008.01639.x     Document Type: Review

References (35)

1. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998 41 : 58 67.
2. Gran JT, Husby G, Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis 1985 44 : 359 67.
3. van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 1997 24 : 2225 9.
4. Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 1999 26 : 966 70.
5. Wanders AJ, van der Heijde D, Landewe RB, Behier JM, Calin A, Olivieri I, Zeidler H, Dougados M. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis. Arthritis Rheum 2005 52 : 1756 65.
6. Dagfinrud H, Hagen KB, Kvien TK. Physiotherapy interventions for ankylosing spondylitis. The Cochrane Database of Systematic Reviews 2004, Issue 4.
7. Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002 46 : 766 73.
8. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995 38 : 499 505.
9. Toussirot E, Lafforgue P, Boucraut J, Despieds P, Schiano A, Bernard D et al. Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol Int 1994 13 : 175 80.
10. Crew MD, Effros RB, Walford RL, Zeller E, Cheroutre H, Brahn E. Transgenic mice expressing a truncated Peromyscus leucopus TNF-alpha gene manifest an arthritis resembling ankylosing spondylitis. J Interferon Cytokine Res 1998 18 : 219 25.
11. Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J et al, and the ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006 54 : 2136 46.
12. Davis JC, Van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum 2003 48 : 3230 36.
13. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004 63 : 1594 600.
14. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002 346 : 1349 56.
15. Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003 48 : 1667 75.
16. Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P et al. The Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005 52 : 582 91.
17. Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002 46 : 755 65.
18. Pavy S, Brophy S, Calin A. Establishment of the minimum clinically important difference for the Bath ankylosing spondylitis indices: a prospective study. J Rheumatol 205 32 : 80 85.
19. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002 359 : 1187 93.
20. Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology 2005 44 : 1525 30.
21. Davis JC, van der Heijde D, Dougados M, Wooley JM. Reductions in health-related quality of life with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005 53 : 494 501.
22. Briot K, Garnero P, Le Henanff A, Dougados M, Roux C. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor treatment. Ann Rheum Dis 2005 64 : 1137 40.
23. Woo J, Lee H, Sung I, Kim T. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007 34 : 1753 9.
24. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005 52 : 2447 51.
25. Braun J, Baraliakos X, Listing J, Davis J, Van der Heijde D, Haibel H et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor agents. Arthritis Rheum 2007 57 : 639 47.
26. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006 65 : 889 94.
27. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum 2007 56 : 2886 95.
28. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005 64 : 1421 6.
29. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H et al. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum 2001 44 : 2862 9.
30. De Bandt M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005 7 : R545 R551.
31. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004 116 : 305 11.
32. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. The ASAS Working Group. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006 65 : 316 20.
33. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI50) to tumour necrosis factor α blockers in ankylosing spondylitis. Ann Rheum Dis 2004 63 : 665 70.
34. Baraliakos X, Listing J, Brandt J, Rudwaleit M, Seiper J, Braun J. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005 7 : R439 44.
35. NICE. Ankylosing spondylitis - adalimumab, etanercept and infliximab. 2nd appraisal consultation document. 2007 Jul cited 22 August 2007 Available from URL : www.nice.org.uk/guidance/TA.